Please enable JavaScript to continue using this application.

Compare $IKT vs $PALI | Chartloom

Compare

$IKT vs $PALI

Inhibikase Therapeutics Inc · Palisade Bio Inc

IKT

Inhibikase Therapeutics Inc

PALI

Palisade Bio Inc

Compare $IKT vs $PALI

Comparing Inhibikase Therapeutics Inc and Palisade Bio Inc

IKTInhibikase Therapeutics Inc

PALIPalisade Bio Inc

IKTInhibikase Therapeutics Inc

Market cap

$309M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

1.0%

52W performance

18.7%

FCF yield

-13.8%

PALIPalisade Bio Inc

Market cap

$267M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-38.4%

52W performance

-23.0%

FCF yield

-6.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

IKT

PALI

Detailed metrics comparison

IKT

Inhibikase Therapeutics Inc

PALI

Palisade Bio Inc

Market Cap

IKT$309M

PALI$267M

Enterprise Value

IKT$278M

PALI$142M

Price

IKT$1.97

PALI$1.54

P/E Ratio

IKTN/A

PALIN/A

P/S Ratio

IKT872.10x

PALI534.63x

EV/Sales

IKT774.58x

PALI284.28x

EV/EBITDA

IKT0.00x

PALI0.00x

P/B Ratio

IKT1.82x

PALI2.06x

P/FCF Ratio

IKTN/A

PALIN/A

EV/FCF

IKT-6.53x

PALI-7.81x

PEG Ratio

IKTN/A

PALIN/A

Forward P/E (NTM)

IKTN/A

PALIN/A

Forward P/S (NTM)

IKTN/A

PALIN/A

Revenue (TTM)

IKT$0

PALI$500K

Revenue Growth (YoY)

IKTN/A

PALIN/A

Forward Rev Growth

IKT0.0%

PALI42864.7%

Gross Margin (TTM)

IKT0.0%

PALI0.0%

Operating Margin (TTM)

IKT0.0%

PALI0.0%

EBITDA Margin (TTM)

IKT0.0%

PALI-7069.6%

Net Margin (TTM)

IKT0.0%

PALI-6388.2%

FCF Margin (TTM)

IKTN/A

PALI-3638.0%

Net Income (TTM)

IKT$-44M

PALI$-32M

FCF (TTM)

IKT$-43M

PALI$-18M

EPS (TTM)

IKT-$0.25

PALI-$0.15

ROE (TTM)

IKT-4690.0%

PALI-3347.0%

ROA (TTM)

IKT-4348.0%

PALI-3179.0%

ROIC (TTM)

IKT-4690.0%

PALI-3345.0%

Cash

IKT$31M

PALI$125M

Debt

IKT$0

PALI$0

Net Cash/Debt

IKT$31M

PALI$125M

Current Ratio (TTM)

IKT15.82x

PALI24.26x

Quick Ratio (TTM)

IKT15.50x

PALI23.97x

Debt/Equity (TTM)

IKT0.00x

PALI0.00x

Debt/Assets (TTM)

IKT0.0%

PALI0.0%

Interest Coverage (TTM)

IKTN/A

PALIN/A

Net Debt/EBITDA (TTM)

IKT0.00x

PALI0.00x

Beta

IKT0.92

PALI1.53

52W Performance

IKT18.7%

PALI-23.0%

YTD Performance

IKT1.0%

PALI-38.4%

% from 52W High

IKT-24.5%

PALI-46.0%

% from 52W Low

IKT48.1%

PALI16.7%

Asset Turnover (TTM)

IKT0.01x

PALI0.00x

FCF Yield (TTM)

IKT-13.8%

PALI-6.8%

Earnings Yield (TTM)

IKT-14.3%

PALI-11.9%

Dividend Yield (TTM)

IKTN/A

PALIN/A

Rule of 40

IKT0.0

PALI-3,638.0

EV/GP/RG

IKTN/A

PALIN/A

Ticker research

View IKT research View PALI research

Metric	IKT Inhibikase Therapeutics Inc	PALI Palisade Bio Inc
Market & Valuation
Market Cap	$309M	$267M
Enterprise Value	$278M	$142M
Price	$1.97	$1.54
P/E Ratio	N/A	N/A
P/S Ratio	872.10x	534.63x
EV/Sales	774.58x	284.28x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.82x	2.06x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.53x	-7.81x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$500K
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	42864.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-7069.6%
Net Margin (TTM)	0.0%	-6388.2%
FCF Margin (TTM)	N/A	-3638.0%
Net Income (TTM)	$-44M	$-32M
FCF (TTM)	$-43M	$-18M
EPS (TTM)	-$0.25	-$0.15
ROE (TTM)	-4690.0%	-3347.0%
ROA (TTM)	-4348.0%	-3179.0%
ROIC (TTM)	-4690.0%	-3345.0%
Financial Health
Cash	$31M	$125M
Debt	$0	$0
Net Cash/Debt	$31M	$125M
Current Ratio (TTM)	15.82x	24.26x
Quick Ratio (TTM)	15.50x	23.97x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.92	1.53
52W Performance	18.7%	-23.0%
YTD Performance	1.0%	-38.4%
% from 52W High	-24.5%	-46.0%
% from 52W Low	48.1%	16.7%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-13.8%	-6.8%
Earnings Yield (TTM)	-14.3%	-11.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-3,638.0
EV/GP/RG	N/A	N/A
Ticker research	View IKT research	View PALI research

Valuation

P/S Ratio

PALI

534.63x

IKT

872.10x

EV/FCF

PALI

-7.81x

IKT

-6.53x

Growth & revenue

Forward Revenue Growth

PALI

42864.7%

IKT

0.0%

Profitability & performance

Gross Margin

IKT

0.0%

PALI

0.0%

ROE

PALI

-3347.0%

IKT

-4690.0%

FCF Yield %

PALI

-6.8%

IKT

-13.8%

52-Week Performance

IKT

18.7%

PALI

-23.0%

Detailed metrics comparison

IKT

Inhibikase Therapeutics Inc

PALI

Palisade Bio Inc

Market Cap

IKT$309M

PALI$267M

Enterprise Value

IKT$278M

PALI$142M

Price

IKT$1.97

PALI$1.54

P/E Ratio

IKTN/A

PALIN/A

P/S Ratio

IKT872.10x

PALI534.63x

EV/Sales

IKT774.58x

PALI284.28x

EV/EBITDA

IKT0.00x

PALI0.00x

P/B Ratio

IKT1.82x

PALI2.06x

P/FCF Ratio

IKTN/A

PALIN/A

EV/FCF

IKT-6.53x

PALI-7.81x

PEG Ratio

IKTN/A

PALIN/A

Forward P/E (NTM)

IKTN/A

PALIN/A

Forward P/S (NTM)

IKTN/A

PALIN/A

Revenue (TTM)

IKT$0

PALI$500K

Revenue Growth (YoY)

IKTN/A

PALIN/A

Forward Rev Growth

IKT0.0%

PALI42864.7%

Gross Margin (TTM)

IKT0.0%

PALI0.0%

Operating Margin (TTM)

IKT0.0%

PALI0.0%

EBITDA Margin (TTM)

IKT0.0%

PALI-7069.6%

Net Margin (TTM)

IKT0.0%

PALI-6388.2%

FCF Margin (TTM)

IKTN/A

PALI-3638.0%

Net Income (TTM)

IKT$-44M

PALI$-32M

FCF (TTM)

IKT$-43M

PALI$-18M

EPS (TTM)

IKT-$0.25

PALI-$0.15

ROE (TTM)

IKT-4690.0%

PALI-3347.0%

ROA (TTM)

IKT-4348.0%

PALI-3179.0%

ROIC (TTM)

IKT-4690.0%

PALI-3345.0%

Cash

IKT$31M

PALI$125M

Debt

IKT$0

PALI$0

Net Cash/Debt

IKT$31M

PALI$125M

Current Ratio (TTM)

IKT15.82x

PALI24.26x

Quick Ratio (TTM)

IKT15.50x

PALI23.97x

Debt/Equity (TTM)

IKT0.00x

PALI0.00x

Debt/Assets (TTM)

IKT0.0%

PALI0.0%

Interest Coverage (TTM)

IKTN/A

PALIN/A

Net Debt/EBITDA (TTM)

IKT0.00x

PALI0.00x

Beta

IKT0.92

PALI1.53

52W Performance

IKT18.7%

PALI-23.0%

YTD Performance

IKT1.0%

PALI-38.4%

% from 52W High

IKT-24.5%

PALI-46.0%

% from 52W Low

IKT48.1%

PALI16.7%

Asset Turnover (TTM)

IKT0.01x

PALI0.00x

FCF Yield (TTM)

IKT-13.8%

PALI-6.8%

Earnings Yield (TTM)

IKT-14.3%

PALI-11.9%

Dividend Yield (TTM)

IKTN/A

PALIN/A

Rule of 40

IKT0.0

PALI-3,638.0

EV/GP/RG

IKTN/A

PALIN/A

Ticker research

View IKT research View PALI research

Metric	IKT Inhibikase Therapeutics Inc	PALI Palisade Bio Inc
Market & Valuation
Market Cap	$309M	$267M
Enterprise Value	$278M	$142M
Price	$1.97	$1.54
P/E Ratio	N/A	N/A
P/S Ratio	872.10x	534.63x
EV/Sales	774.58x	284.28x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.82x	2.06x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.53x	-7.81x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$500K
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	42864.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-7069.6%
Net Margin (TTM)	0.0%	-6388.2%
FCF Margin (TTM)	N/A	-3638.0%
Net Income (TTM)	$-44M	$-32M
FCF (TTM)	$-43M	$-18M
EPS (TTM)	-$0.25	-$0.15
ROE (TTM)	-4690.0%	-3347.0%
ROA (TTM)	-4348.0%	-3179.0%
ROIC (TTM)	-4690.0%	-3345.0%
Financial Health
Cash	$31M	$125M
Debt	$0	$0
Net Cash/Debt	$31M	$125M
Current Ratio (TTM)	15.82x	24.26x
Quick Ratio (TTM)	15.50x	23.97x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.92	1.53
52W Performance	18.7%	-23.0%
YTD Performance	1.0%	-38.4%
% from 52W High	-24.5%	-46.0%
% from 52W Low	48.1%	16.7%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-13.8%	-6.8%
Earnings Yield (TTM)	-14.3%	-11.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-3,638.0
EV/GP/RG	N/A	N/A
Ticker research	View IKT research	View PALI research